Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Zhao, Jiangning ^a   Xu, Zhenshu ^b   Liu, Delong ^c   Lu, Quanyi ^a  

^a ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b Fujian Union Hospital   (China)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GEMCITABINE; OXALIPLATIN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERABILITY; HUMAN; INDOLENT LYMPHOMA; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84865251730     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-38     Document Type: Review

References (59)

1. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000, 51(6):634-641. 10.1046/j.1365-3083.2000.00745.x, 10849376.
2. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63(8):803-843. 10.2165/00003495-200363080-00005, 12662126.
3. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006, 24(19):3121-3127.
4. Coiffier B. Rituximab in diffuse large B-cell lymphoma. Clinical advances in hematology & oncology: H&O 2004, 2(3):156-157. 3420227, 22919395.
5. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007, 26(25):3603-3613. 10.1038/sj.onc.1210376, 17530014.
6. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92(6):1927-1932.
7. Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL. Aggressive lymphoma: improving treatment outcome with rituximab. Anti-cancer drugs 2002, 13(Suppl 2):S43-S50.
8. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7(5):379-391. 10.1016/S1470-2045(06)70664-7, 16648042.
9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Eng J Med 2002, 346(4):235-242.
10. Coiffier B. Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nat Clin Pract Oncol 2006, 3(11):594-595.
11. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002, 29(2 Suppl 6):18-22.
12. Tilly H, Morschhauser F, Salles G, Casasnovas RO, Feugier P, Molina TJ, Jardin F, Terriou L, Haioun C, Coiffier B. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma 2012, Leukemia official journal of the Leukemia Society of America, Leukemia Research Fund, UK.
13. Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Briere J, Reyes F, Gaulard P, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2008, 22(10):1917-1924.
14. Wu ZL, Song YQ, Shi YF, Zhu J. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011, 4(1):31. 10.1186/1756-8722-4-31, 3163635, 21806788.
15. Johnson P. New targets for lymphoma treatment. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2008, 19(Suppl 4)):iv56-iv59.
16. Johnston P, Yuan R, Cavalli F, Witzig T. Targeted therapy in lymphoma. J Hematol Oncol 2010, 3(1):45. 10.1186/1756-8722-3-45, 3003620, 21092307.
17. Sacco A, Issa G, Zhang Y, Liu Y, Maiso P, Ghobrial I, Roccaro A. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol 2010, 3(1):38. 10.1186/1756-8722-3-38, 2964547, 20929526.
18. Budhu A, Ji J, Wang X. The clinical potential of microRNAs. J Hematol Oncol 2010, 3(1):37. 10.1186/1756-8722-3-37, 2958878, 20925959.
19. Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom R, Coleman M, Leonard JP. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010, 116(23):5432-5439. 10.1002/cncr.25509, 20665890.
20. Wang J, Ke X-Y. The Four types of Tregs in malignant lymphomas. J Hematol Oncol 2011, 4(1):50. 10.1186/1756-8722-4-50, 3253040, 22151904.
21. Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012, 30(3)):1232-1240.
22. Hornberger J, Reyes C, Shewade A, Lerner S, Friedmann M, Han L, Gutierrez H, Satram-Hoang S, Keating MJ. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53(2):225-234. 10.3109/10428194.2011.605918, 21824050.
23. Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioltelli P, Sacchi S, Ricci F, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012, 118(2):434-443. 10.1002/cncr.26303, 21732338.
24. Zhou Y, Tang G, Medeiros LJ, McDonnell TJ, Keating MJ, Wierda WG, Wang SA. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2012, 25(2):237-245.
25. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005, 23(18):4079-4088.
26. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174. 10.1016/S0140-6736(10)61381-5, 20888994.
27. Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Horning SJ. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. ASH Annual Meeting Abstracts 2011, 118(21):LBA-6.
28. Williams ME, Hong F, Kahl BS, Gascoyne RD, Wagner LI, Krauss JC, Horning SJ. A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. ASCO Meeting Abstracts 2012, 30(15_suppl)):8007.
29. Brewster M, Hurst D, Chai A, Lee EJ, Upadhyaya GH, Dakhil SR. Pharmacokinetics (PK) and pharmacodynamics (PD) of rituximab administered by faster infusion in patients with previously untreated diffuse large B-cell (DLBCL) or follicular lymphoma (FL). ASCO Meeting Abstracts 2012, 30(15_suppl)):6591.
30. Federico M, Luminari S, Dondi A, Sacchi S, Franco V, Pileri S, Lombardo M, Rossi G, Arcaini L, Chisesi T, et al. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). ASCO Meeting Abstracts 2012, 30(15_suppl):8006.
31. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377(9759):42-51. 10.1016/S0140-6736(10)62175-7, 21176949.
32. Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol 2012, 91(7):1013-1022. 10.1007/s00277-012-1422-5, 22349722.
33. Montillo M. Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial. Expert Rev Hematol 2012, 5(1):43-46. 10.1586/ehm.11.75, 22272704.
34. Chang JE, Kahl BS. Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma 2012, 53(7):1249-1250. 10.3109/10428194.2011.654342, 22220986.
35. Sanchez-Gonzalez B, Penalver FJ, Medina A, Guillen H, Calleja M, Gironella M, Arranz R, Sebastian E, de Ona R, Canovas A, et al. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. Leuk Res 2012, 36(6):709-714. 10.1016/j.leukres.2011.10.024, 22154023.
36. Magyari F, Simon Z, Barna S, Udvardy M, Varoczy L, Illes A. Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation. Hematol Oncol 2012, 30(2):98-100. 10.1002/hon.1004, 22034208.
37. Rummel MJ, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. ASCO Meeting Abstracts 2012, 30(18_suppl)):3.
38. Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Delaloye AB, Press OW, Ketterer N. Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2011, 52(6):896-900.
39. Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP, Ketterer N. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 2006, 94(12):1770-1776. 10.1038/sj.bjc.6603166, 2361356, 16685263.
40. Davies AJ, Rohatiner AZ, Howell S, Britton KE, Owens SE, Micallef IN, Deakin DP, Carrington BM, Lawrance JA, Vinnicombe S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004, 22(8):1469-1479.
41. Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2004, 4(1):18-26. 10.1586/14737140.4.1.18, 14748653.
42. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2009, 20(4):709-714.
43. Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2009, 50(11):1837-1843.
44. Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, Itoh K, Okamoto S, Taniwaki M, Tsukamoto N, et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009, 100(1):158-164. 10.1111/j.1349-7006.2008.00999.x, 19018755.
45. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Vitolo U, Perrotti A, Fina M, Derenzini E, Baccarani M. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008, 112(4):856-862. 10.1002/cncr.23236, 18189293.
46. Press OW, Unger JM, LeBlanc ML, Rimsza LM, Friedberg JW, Czuczman MS, Kaminski MS, Braziel RM, Spier CM, Maloney DG, et al. A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. ASCO Meeting Abstracts 2012, 30(15_suppl):8001.
47. Corazzelli G, Frigeri F, Marcacci G, Capobianco G, Arcamone M, Becchimanzi C, Russo F, Pinto A. Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma. ASCO Meeting Abstracts 2009, 27(15S):8579.
48. El Gnaoui T, Dupuis J, Belhadj K, Rahmouni A, Copie-Bergman C, Gaillard I, Divine M, Tabah-Fisch IM, Reyes F, Haioun C. Rituximab, gemcitabine and oxaliplatin (R-GEMOX): An effective regimen for relapsed and refractory B-cell lymphoma. ASCO Meeting Abstracts 2006, 24(18_suppl)):7562.
49. Tsimberidou AM, Wierda WG, Badoux X, Wen S, Plunkett W, O'Brien SM, Kipps TJ, Jones JA, Kantarjian H, Keating MJ. Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). ASCO Meeting Abstracts 2010, 28(15_suppl):6521.
50. Tsimberidou AM, Wierda WG, Plunkett WK, O''Brien S, Lerner S, Smith SC, Kantarjian HM, Keating MJ. hase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts 2009, 27(15S)):7031.
51. Crescentini RM, Sweet KL, Liu J, Liboy I, Dalia S, Chavez JC, Bello CM, Sokol L, Sotomayor EM, Cabanillas F, et al. An update on gemcitabine, rituximab, and oxaliplatin in combination for relapsed/refractory non-Hodgkin lymphomas. ASCO Meeting Abstracts 2012, 30(15_suppl)):8084.
52. Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010, 3(1):8. 10.1186/1756-8722-3-8, 2830959, 20149254.
53. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011, 4:16. 10.1186/1756-8722-4-16, 3103487, 21504625.
54. Ge X, Wang X. Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol 2010, 3(1):33. 10.1186/1756-8722-3-33, 2954871, 20843302.
55. Elbaz H, Stueckle T, Tse W, Rojanasakul Y, Dinu C. Digitoxin and its analogs as novel cancer therapeutics. Experimental Hematology & Oncology 2012, 1(1):4. 10.1186/2162-3619-1-4, 23055339.
56. Brown JR, Sharman JP, Harb WA, Kelly KR, Schreeder MT, Sweetenham JW, Barr PM, Foran JM, Gabrilove JL, Kipps TJ, et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). ASCO Meeting Abstracts 2012, 30(15_suppl)):8032.
57. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Sharman JP, Flinn IW, Grant BW, Heerema NA, Johnson AJ, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. ASCO Meeting Abstracts 2012, 30(15_suppl):6507.
58. Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer SM, Woyach JA, Johnson AJ, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. ASCO Meeting Abstracts 2012, 30(15_suppl):6508.
59. O'Brien SM, Barrientos JC, Flinn IW, Barr PM, Burger JA, Navarro T, James DF, Hedrick E, Friedberg JW, Brown JR. Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study. ASCO Meeting Abstracts 2012, 30(15_suppl):6515.